Participants 102 296 10
16 patients with relapsing non-Hodgkin's malignant lymphomas considered as clinical stage I or II were treated by an association of chemo + radiotherapy and thereafter by maintenance BCG therapy
Participants 298 459 3
5 of them were included in a randomized trial and have a significantly different disease-free survival from patients receiving the same treatment but without BCG
